<DOC>
	<DOCNO>NCT01136239</DOCNO>
	<brief_summary>This study investigate add-on effect high dose NAC ( 600mg tablet twice daily ) reduction airtrapping airway resistance stable COPD patient well study 's effect reduce exacerbation , improve exercise capacity quality life stable COPD patient .</brief_summary>
	<brief_title>The Effect High Dose N-acetylcysteine Airtrapping Airway Resistance Chronic Obstructive Pulmonary Disease ( COPD ) Patients</brief_title>
	<detailed_description>Background : The mucolytic antioxidant effect N-acetylcysteine ( NAC ) may great value treatment COPD patient . However , previous study fail demonstrate beneficial effect NAC . This may due insufficient dose NAC use well inadequate outcome parameter measure past study . Objective study : This study investigate add-on effect high dose NAC ( 600mg tablet twice daily ) reduction airtrapping airway resistance stable COPD patient well study 's effect reduce exacerbation , improve exercise capacity quality life stable COPD patient . Study design : Randomized double blind placebo control trial Kwong Wah Hospital Methodology : Patients recruit Kwong Wah Hospital fulfill spirometric criterion COPD . Eligible subject randomize treatment ( NAC 600mg tablet twice daily ) placebo group completion run period . NAC placebo prescribe accordingly addition usual therapy . Both patient investigator blind group allocation . Baseline assessment do patient follow 16th week 52th week study . During follow-up visit , hyperinflation parameter like inspiratory capacity ( IC ) measure plethysmography . Airway resistance measure plethysmography impulse oscillometry machine . Exercise capacity ( 6 min walk distance ) quality life also record follow . The difference parameter 2 group ( drug placebo group ) analyszed Repeated measure ANOVA test</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Acetylcysteine</mesh_term>
	<mesh_term>N-monoacetylcystine</mesh_term>
	<criteria>Spirometry diagnose COPD FEV1/FVC ratio le 70 % FEV1 le 80 % predict clinically stable exacerbation free past 4 week history least one COPD exacerbation past one year patient allergic intolerant NAC Recent use NAC past one month history asthma , non COPD respiratory disorder like bronchiectasis , pneumoconiosis active pulmonary infection patient long term steroid patient long term oxygen therapy non invasive ventilation</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>COPD</keyword>
	<keyword>N-acetylcysteine</keyword>
	<keyword>airtrapping</keyword>
	<keyword>airway resistance</keyword>
	<keyword>antioxidant</keyword>
</DOC>